Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-3283-4200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
OptionableNot Optionable
VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions
What is VERONA PHARMA P/S's stock symbol?
VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."
How were VERONA PHARMA P/S's earnings last quarter?
VERONA PHARMA P/S (NASDAQ:VRNA) released its earnings results on Tuesday, November, 6th. The company reported ($0.23) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.49) by $0.26. View VERONA PHARMA P/S's Earnings History.
When is VERONA PHARMA P/S's next earnings date?
What price target have analysts set for VRNA?
5 analysts have issued 1 year target prices for VERONA PHARMA P/S's stock. Their forecasts range from $25.00 to $56.00. On average, they anticipate VERONA PHARMA P/S's stock price to reach $34.80 in the next twelve months. This suggests a possible upside of 454.1% from the stock's current price. View Analyst Price Targets for VERONA PHARMA P/S.
What is the consensus analysts' recommendation for VERONA PHARMA P/S?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VERONA PHARMA P/S.
What are Wall Street analysts saying about VERONA PHARMA P/S stock?
Here are some recent quotes from research analysts about VERONA PHARMA P/S stock:
- 1. Wedbush analysts commented, "FDA approved Cabometyx (cabozantinib) for patients with advanced HCC post sorafenib treatment. The approval is an important milestone supporting cabozantinib growth beyond RCC and MTC into the large HCC opportunity. The approval is based on Ph3 Celestial data demonstrating statistically significant improvements in OS of cabozantinib (10.2 months) vs placebo (8.0 months). Median PFS was more than doubled with cabozantinib (5.2 months) vs placebo (1.9 months). Safety was acceptable with 16% discontinuations on drug. We expect an immediate launch since sales force was prepared and a small impact on SG&A. We expect launch ramp in HCC slightly below RCC despite the unmet need, since HCC treatment regimen is less well established and involves outsized use of radiation therapy. HCC approval should support continued cabozantinib growth." (1/14/2019)
- 2. According to Zacks Investment Research, "Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. " (11/10/2018)
Has VERONA PHARMA P/S been receiving favorable news coverage?
News articles about VRNA stock have trended very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. VERONA PHARMA P/S earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are some of VERONA PHARMA P/S's key competitors?
Some companies that are related to VERONA PHARMA P/S include Insys Therapeutics (INSY), ZIOPHARM Oncology (ZIOP), Evelo Biosciences (EVLO), BioDelivery Sciences International (BDSI), Achillion Pharmaceuticals (ACHN), Lannett (LCI), OptiNose (OPTN), BIOFRONTERA AG/ADR (BFRA), Merus (MRUS), Albireo Pharma (ALBO), Kalvista Pharmaceuticals (KALV), Dermira (DERM), Neptune Wellness Solutions (NEPT), Minerva Neurosciences (NERV) and Kadmon (KDMN).
Who are VERONA PHARMA P/S's key executives?
VERONA PHARMA P/S's management team includes the folowing people:
- Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 63)
- Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
- Ms. Claire Louise Poll B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 51)
- Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 56)
- Mr. Richard Hennings, Commercial Director (Age 48)
When did VERONA PHARMA P/S IPO?
(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.
How do I buy shares of VERONA PHARMA P/S?
Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VERONA PHARMA P/S's stock price today?
One share of VRNA stock can currently be purchased for approximately $6.28.
How big of a company is VERONA PHARMA P/S?
VERONA PHARMA P/S has a market capitalization of $82.44 million. The company earns $-26,410,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. VERONA PHARMA P/S employs 15 workers across the globe.
What is VERONA PHARMA P/S's official website?
How can I contact VERONA PHARMA P/S?
VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]
MarketBeat Community Rating for VERONA PHARMA P/S (NASDAQ VRNA)
MarketBeat's community ratings are surveys of what our community members think about VERONA PHARMA P/S and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
